Overview

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
A randomized, controlled, open-label multicenter trial to assess the safety and efficacy of 3 oxaliplatin-fluoropyrimidine containing regimens (mFOLFOX6; bFOL; XELOX) + Bevacizumab (TREE1 and TREE2) as first line therapy of advanced metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Bevacizumab
Oxaliplatin